On 14 December 2018, orphan designation (EU/3/18/2118) was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome.
The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in August 2019.
|Disease / condition||
Treatment of Hutchinson-Gilford progeria
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.